Panitumumab is a complete human (natural) monoclonal antibody of the IgG2 type, which is produced inside the mammalian cell line (CHO) using recombinant DNA technology.
Panitumumab with a strong affinity, as well as specificity, is synthesized with human endings of EGFR (skin growth factor). The EGFR receptor is a glycoprotein of the transmembrane form, which is part of the subfamily of type 1 of the tyrosine kinase terminus, which includes both EGFR (HER1 / c-ErbB-1 factor) and HER2, and HER3 plus HER4. The EGFR receptor helps the cell growth inside healthy epithelial tissues (this includes the hair follicles and the skin), and is also expressed in the field of most cellular neoplasms.
The synthesis of panitumumab occurs with the ligand binding region of the EGFR receptor, which slows down the endophosphate autophosphorylation process, which is provoked by all the existing EGFR receptor ligands. Synthesis of the active ingredient with the EGFR factor facilitates the internalization of the end, inhibits cell growth, induces apoptosis, and in addition reduces the production of IL-8, as well as a growth factor of the endothelial type within the vessels.
KRAS type genes, as well as NRAS, have a close relationship with parts of the RAS family of oncogenes. The above genes encode small processes synthesized with GTP-protein (they participate in signal transduction processes). A number of irritant substances (including the EGFR receptor stimulus) help activation of KRAS with NRAS, and they in turn help stimulate the functions of other proteins located inside the cells, and also promote cellular reproduction, as well as their survival and processes angiogenesis.
Activation of mutational processes inside genes like RAS is usually carried out in a variety of human tumors, and in addition participates in the progression of neoplasm and oncogenesis.